Seeking Alpha

Jefferies initiates Stemline Therapeutics with a Buy; shares higher

  • Stemline Therapeutics (STML +5.7%) moves up today after Jefferies initiates coverage with a Buy and a hefty $60 price target.
  • Jefferies says that STML's lead drug, SL-401, is entering pivotal trials in 2014 for the treatment of BPDCN, a rare lymphoma, and third-line acute myeloid leukemia.
  • The firm views response rates in both settings as robust, including durable complete responses, after a single cycle of treatment, and believes that even better efficacy could be achieved with multiple SL-401 cycles. It estimates SL-401 peak sales of over $500M.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|